Thu 8 Oct 2026 International edition

Healthcare News & Policy Decoding the Cholesterol Divide: How Genetics and Saturated Fat Dictate Low-Carb Outcomes

Hematology & Blood Research Unlocking the Blueprint of Cure: Why Certain Cancers Succumb to Chemotherapy While Others Resist

Healthcare News & Policy The Biological Bomb: Stanford Researchers Discover an Exploding Immune Cell in Flatworms That Defies Modern Immunology

Clinical Immunology Johns Hopkins scientists develop nose spray DNA vaccine for tuberculosis

Oncology & Cancer Research Breaking the Immunotherapy Barrier: University of Chicago Researchers Harness Engineered Probiotics to Tackle Pancreatic Cancer

Pathology & Histology Executive Overview: A New Paradigm in Computational Pathology

Public Health & Epidemiology Keeping Older Adults on Their Feet: A Definitive Meta-Analysis Proves Exercise Significantly Cuts Fall-Related Fractures and Severe Injuries

Medical Biotechnology Unlocking the Iceman’s Microbiome: How Ötzi the Mummy Continues to Rewrite Microbiology, History, and Industrial Science

Public Health & Epidemiology Korean medicine use is associated with reduced lumbar surgery and opioid prescriptions in lumbar disc herniation: a nationwide cohort study

Medical Devices & Lab Automation Mapping the Highway of Life: Researchers Unveil the World’s First Comprehensive Human Vagus Nerve Atlas

Laboratory Medicine Revolutionizing Particle Physics: How Light Field Photography and AI Are Eliminating the Million-Component Bottleneck

Clinical Trials & Research The Fault Lines of Oncology Innovation: How Federal and Industry-Backed Cancer Trials Shape Modern Medicine Amid Mounting Funding Pressures

Archive

Tag: ctim

Strategic Pivot in Oncology: Context Therapeutics Axes CT-95 Program to Preserve Cash and Double Down on Pipeline Assets CTIM-76 and CT-202

Clinical Trials & Research

Strategic Pivot in Oncology: Context Therapeutics Axes CT-95 Program to Preserve Cash and Double Down on Pipeline Assets CTIM-76 and CT-202

Executive Overview In a decisive move emblematic of the hyper-selective, risk-averse climate currently dominating the biotech sector, Philadelphia-based Context Therapeutics...

7 Aug 2026